Raymond Alexanian

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Drug Resistance

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Jagannath Sundar; Barlogie Bart; Berenson James R; Siegel David S; Irwin David; Richardson Paul G; Niesvizky Ruben; Alexanian Raymond; Limentani Steven A; Alsina Melissa; Esseltine Dixie-Lee; Anderson Kenneth C
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
Wang M; Giralt S; Delasalle K; Handy B; Alexanian R
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
Christoforidou Anna V; Saliba Rima M; Williams Patricia; Qazilbash Muzaffar; Roden Linda; Aleman Ana; Weber Donna; Mendoza Floralyn; Podoloff Donald; Wendt Richard; Breitz Hazel; Alexanian Raymond; Champlin Richard; Giralt Sergio
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Raymond Alexanian (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2008: Jagannath Sundar; Barlogie Bart; Berenson James R; Siegel David S; Irwin David; Richardson Paul G; Niesvizky Ruben; Alexanian Raymond; Limentani Steven A; Alsina Melissa; Esseltine Dixie-Lee; Anderson Kenneth C
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
British journal of haematology 2008;143(4):537-40.
2007: Wang M; Giralt S; Delasalle K; Handy B; Alexanian R
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
Hematology (Amsterdam, Netherlands) 2007;12(3):235-9.
2007: Christoforidou Anna V; Saliba Rima M; Williams Patricia; Qazilbash Muzaffar; Roden Linda; Aleman Ana; Weber Donna; Mendoza Floralyn; Podoloff Donald; Wendt Richard; Breitz Hazel; Alexanian Raymond; Champlin Richard; Giralt Sergio
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2007;13(5):543-9.
2007: Thomas Sheeba; Alexanian Raymond
Current treatment strategies for multiple myeloma.
Clinical lymphoma & myeloma 2007;7 Suppl 4():S139-44.
2006: Richardson Paul G; Briemberg Hannah; Jagannath Sundar; Wen Patrick Y; Barlogie Bart; Berenson James; Singhal Seema; Siegel David S; Irwin David; Schuster Michael; Srkalovic Gordan; Alexanian Raymond; Rajkumar S Vincent; Limentani Steven; Alsina Melissa; Orlowski Robert Z; Najarian Kevin; Esseltine Dixie; Anderson Kenneth C; Amato Anthony A
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3113-20.
2005: Berenson James R; Jagannath Sundar; Barlogie Bart; Siegel David T; Alexanian Raymond; Richardson Paul G; Irwin David; Alsina Melissa; Rajkumar S Vincent; Srkalovic Gordon; Singhal Seema; Limentani Steven; Niesvizky Ruben; Esseltine Dixie L; Trehu Elizabeth; Schenkein David P; Anderson Kenneth
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Cancer 2005;104(10):2141-8.
2005: Moulopoulos L A; Gika D; Anagnostopoulos A; Delasalle K; Weber D; Alexanian R; Dimopoulos M A
Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(11):1824-8.
2005: Wang Michael; Weber Donna M; Delasalle Kay; Alexanian Raymond
Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
American journal of hematology 2005;79(3):194-7.
2005: Amit-Vazina M; Shishodia S; Harris D; Van Q; Wang M; Weber D; Alexanian R; Talpaz M; Aggarwal B B; Estrov Z
Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells.
British journal of cancer 2005;93(1):70-80.
2005: Jagannath Sundar; Barlogie Bart; Berenson James R; Singhal Seema; Alexanian Raymond; Srkalovic Gordan; Orlowski Robert Z; Richardson Paul G; Anderson Jessica; Nix Darrell; Esseltine Dixie L; Anderson Kenneth C;
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Cancer 2005;103(6):1195-200.
2005: Dimopoulos Meletios A; Merlini Giampaolo; Leblond Veronique; Anagnostopoulos Athanasios; Alexanian Raymond
How we treat Waldenström's macroglobulinemia.
Haematologica 2005;90(1):117-25.
2004: Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson P G; Niesvizky R; Alexanian R; Limentani S A; Alsina M; Adams J; Kauffman M; Esseltine D-L; Schenkein D P; Anderson K C
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
British journal of haematology 2004;127(2):165-72.
2004: Dimopoulos Meletios A; Alexanian Raymond; Gika Dimitra; Anagnostopoulos Athanasios; Zervas Constantinos; Zomas Athanassios; Kyrtsonis Marie C; Anagnostopoulos Nicolaos; Pangalis Gerassimos A; Weber Donna M
Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.
Leukemia & lymphoma 2004;45(10):2057-61.
2004: Alexanian R; Weber D; Delasalle K; Handy B; Champlin R; Giralt S
Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma.
Bone marrow transplantation 2004;34(3):229-34.
2004: Anagnostopoulos Athanasios; Aleman Ana; Ayers Gregory; Donato Michele; Champlin Richard; Weber Donna; Alexanian Raymond; Giralt Sergio
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Cancer 2004;100(12):2607-12.
2004: Donato Michele L; Aleman Ana; Champlin Richard E; Weber Donna; Alexanian Raymond; Ippoliti Cindy M; de Lima Marcos; Anagnostopoulos Athanasios; Giralt Sergio
High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma.
Leukemia & lymphoma 2004;45(4):755-9.
2004: Bharti Alok C; Shishodia Shishir; Reuben James M; Weber Donna; Alexanian Raymond; Raj-Vadhan Saroj; Estrov Zeev; Talpaz Moshe; Aggarwal Bharat B
Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis.
Blood 2004;103(8):3175-84.
2004: Anagnostopoulos A; Aleman A; Yang Y; Donato M; Weber D; Champlin R; Smith T; Alexanian R; Giralt S
Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy.
Bone marrow transplantation 2004;33(6):623-8.
2003: Alexanian Raymond; Weber Donna; Anagnostopoulos Athanasios; Delasalle Kay; Wang Michael; Rankin Kim
Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.
Seminars in hematology 2003;40(4 Suppl 4):3-7.
2003: Giralt Sergio; Bensinger William; Goodman Mark; Podoloff Donald; Eary Janet; Wendt Richard; Alexanian Raymond; Weber Donna; Maloney David; Holmberg Leona; Rajandran Joseph; Breitz Hazel; Ghalie Richard; Champlin Richard
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials.
Blood 2003;102(7):2684-91.
2003: Richardson Paul G; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Srkalovic Gordan; Alsina Melissa; Alexanian Raymond; Siegel David; Orlowski Robert Z; Kuter David; Limentani Steven A; Lee Stephanie; Hideshima Teru; Esseltine Dixie-Lee; Kauffman Michael; Adams Julian; Schenkein David P; Anderson Kenneth C
A phase 2 study of bortezomib in relapsed, refractory myeloma.
The New England journal of medicine 2003;348(26):2609-17.
2003: Anagnostopoulos Athanasios; Weber Donna; Rankin Kim; Delasalle Kay; Alexanian Raymond
Thalidomide and dexamethasone for resistant multiple myeloma.
British journal of haematology 2003;121(5):768-71.
2003: Weber Donna M; Dimopoulos Meletios A; Delasalle Kay; Rankin Kim; Gavino Maria; Alexanian Raymond
2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
Seminars in oncology 2003;30(2):243-7.
2003: Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
Asymptomatic Waldenstrom's macroglobulinemia.
Seminars in oncology 2003;30(2):206-10.
2003: Kyle Robert A; Treon Steven P; Alexanian Raymond; Barlogie Bart; Björkholm Magnus; Dhodapkar Madhav; Lister T Andrew; Merlini Giampaolo; Morel Pierre; Stone Marvin; Branagan Andrew R; Leblond Véronique
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Seminars in oncology 2003;30(2):116-20.
2003: Weber Donna; Rankin Kim; Gavino Maria; Delasalle Kay; Alexanian Raymond
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(1):16-9.
2002: Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno N T; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
Bone marrow transplantation 2002;30(6):367-73.
2002: Alexanian R; Weber D; Giralt S; Delasalle K
Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(7):1116-9.
2002: Wilder Richard B; Ha Chul S; Cox James D; Weber Donna; Delasalle Kay; Alexanian Raymond
Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone.
Cancer 2002;94(5):1532-7.
2001: Alexanian R; Weber D
Recent advances in treatment of multiple myeloma and Waldenström's macroglobulinemia.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2001;55(9-10):550-2.
2001: Mansoor A; Medeiros L J; Weber D M; Alexanian R; Hayes K; Jones D; Lai R; Glassman A; Bueso-Ramos C E
Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course.
American journal of clinical pathology 2001;116(4):543-9.
2001: Alexanian R; Weber D; Giralt S; Dimopoulos M; Delasalle K; Smith T; Champlin R
Impact of complete remission with intensive therapy in patients with responsive multiple myeloma.
Bone marrow transplantation 2001;27(10):1037-43.
2001: Anagnostopoulos A; Dimopoulos M A; Aleman A; Weber D; Alexanian R; Champlin R; Giralt S
High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia.
Bone marrow transplantation 2001;27(10):1027-9.
2001: Shimoni A; Smith T L; Aleman A; Weber D; Dimopoulos M; Anderlini P; Andersson B; Claxton D; Ueno N T; Khouri I; Donato M; Korbling M; Alexanian R; Champlin R; Giralt S
Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
Bone marrow transplantation 2001;27(8):821-8.
2000: Alexanian R; Weber D; Dimopoulos M; Delasalle K; Smith T L
Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma.
American journal of hematology 2000;65(3):204-9.
2000: Dimopoulos M A; Moulopoulos L A; Maniatis A; Alexanian R
Solitary plasmacytoma of bone and asymptomatic multiple myeloma.
Blood 2000;96(6):2037-44.
2000: Dimopoulos M A; Moulopoulos L A; Datseris I; Weber D; Delasalle K; Gika D; Alexanian R
Imaging of myeloma bone disease--implications for staging, prognosis and follow-up.
Acta oncologica (Stockholm, Sweden) 2000;39(7):823-7.
1999: Liebross R H; Ha C S; Cox J D; Weber D; Delasalle K; Alexanian R
Clinical course of solitary extramedullary plasmacytoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1999;52(3):245-9.
1999: Alexanian R; Weber D; Liu F
Differential diagnosis of monoclonal gammopathies.
Archives of pathology & laboratory medicine 1999;123(2):108-13.
1998: Liebross R H; Ha C S; Cox J D; Weber D; Delasalle K; Alexanian R
Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy.
International journal of radiation oncology, biology, physics 1998;41(5):1063-7.
1998: Seong C; Delasalle K; Hayes K; Weber D; Dimopoulos M; Swantkowski J; Huh Y; Glassman A; Champlin R; Alexanian R
Prognostic value of cytogenetics in multiple myeloma.
British journal of haematology 1998;101(1):189-94.
1997: Weber D M; Dimopoulos M A; Moulopoulos L A; Delasalle K B; Smith T; Alexanian R
Prognostic features of asymptomatic multiple myeloma.
British journal of haematology 1997;97(4):810-4.
1997: Giralt S; Weber D; Colome M; Dimopoulos M; Mehra R; Van Besien K; Gajewski J; Andersson B; Khouri I; Przepiorka D; von Wolff B; Delasalle K; Korbling M; Seong D; Alexanian R; Champlin R
Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):667-73.
1996: Dimopoulos M A; Weber D; Kantarjian H; Delasalle K B; Alexanian R
HyperCVAD for VAD-resistant multiple myeloma.
American journal of hematology 1996;52(2):77-81.
1995: Daliani D; Weber D; Alexanian R
Light-heavy chain deposition disease progressing to multiple myeloma.
American journal of hematology 1995;50(4):296-8.
1995: Weber D; Dimopoulos M; Sinicrope F; Alexanian R
VAD-cyclosporine therapy for VAD-resistant multiple myeloma.
Leukemia & lymphoma 1995;19(1-2):159-63.
1995: Alexanian R; Dimopoulos M A; Delasalle K B; Hester J; Champlin R
Myeloablative therapy for primary resistant multiple myeloma.
Stem cells (Dayton, Ohio) 1995;13 Suppl 2():118-21.
1995: Moulopoulos L A; Dimopoulos M A; Smith T L; Weber D M; Delasalle K B; Libshitz H I; Alexanian R
Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(1):251-6.
1995: Dimopoulos M A; Weber D; Delasalle K B; Keating M; Alexanian R
Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(1):49-52.
1994: Alexanian R; Dimopoulos M A; Hester J; Delasalle K; Champlin R
Early myeloablative therapy for multiple myeloma.
Blood 1994;84(12):4278-82.
1994: Dimopoulos M A; Kantarjian H; Weber D; O'Brien S; Estey E; Delasalle K; Rose E; Cabanillas F; Keating M; Alexanian R
Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(12):2694-8.
1994: Dimopoulos M A; Palumbo A; Delasalle K B; Alexanian R
Primary plasma cell leukaemia.
British journal of haematology 1994;88(4):754-9.
1994: Dimopoulos M A; Arbuck S; Huber M; Weber D; Luckett R; Delasalle K; Alexanian R
Primary therapy of multiple myeloma with paclitaxel (taxol).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(8):757-9.
1994: Dimopoulos M A; Hester J; Huh Y; Champlin R; Alexanian R
Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma.
British journal of haematology 1994;87(4):730-4.
1994: Vesole D H; Barlogie B; Jagannath S; Cheson B; Tricot G; Alexanian R; Crowley J
High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants.
Blood 1994;84(3):950-6.
1994: Dimopoulos M A; Weber D M; Hester J; Delasalle K; Champlin R; Alexanian R
Intensive sequential therapy for VAD-resistant multiple myeloma.
Leukemia & lymphoma 1994;13(5-6):479-84.
1994: Dimopoulos M A; Alexanian R
Waldenstrom's macroglobulinemia.
Blood 1994;83(6):1452-9.
1994: Dimopoulos M A; Weber D M; Kantarjian H; Keating M; Alexanian R
2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):288-9.
1994: Alexanian R; Dimopoulos M
The treatment of multiple myeloma.
The New England journal of medicine 1994;330(7):484-9.
1994: Alexanian R; Dimopoulos M; Smith T; Delasalle K; Barlogie B; Champlin R
Limited value of myeloablative therapy for late multiple myeloma.
Blood 1994;83(2):512-6.
1993: Dimopoulos M A; Weber D; Delasalle K B; Alexanian R
Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma.
Cancer 1993;72(9):2589-92.
1993: Dimopoulos M A; Alexanian R; Przepiorka D; Hester J; Andersson B; Giralt S; Mehra R; van Besien K; Delasalle K B; Reading C
Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma.
Blood 1993;82(8):2324-8.
1993: Moulopoulos L A; Dimopoulos M A; Weber D; Fuller L; Libshitz H I; Alexanian R
Magnetic resonance imaging in the staging of solitary plasmacytoma of bone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(7):1311-5.
1993: Dimopoulos M A; Delasalle K B; Champlin R; Alexanian R
Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma.
British journal of haematology 1993;83(2):240-4.
1993: Dimopoulos M A; Kantarjian H; Estey E; O'Brien S; Delasalle K; Keating M J; Freireich E J; Alexanian R
Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine.
Annals of internal medicine 1993;118(3):195-8.
1993: Dimopoulos M A; Moulopoulos A; Smith T; Delasalle K B; Alexanian R
Risk of disease progression in asymptomatic multiple myeloma.
The American journal of medicine 1993;94(1):57-61.
1993: Dimopoulos M A; O'Brien S; Kantarjian H; Estey E E; Keating M J; Alexanian R
Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Leukemia & lymphoma 1993;11 Suppl 2():105-8.
1992: Alexanian R; Dimopoulos M A; Delasalle K; Barlogie B
Primary dexamethasone treatment of multiple myeloma.
Blood 1992;80(4):887-90.
1992: Dimopoulos M A; Moulopoulos A; Delasalle K; Alexanian R
Solitary plasmacytoma of bone and asymptomatic multiple myeloma.
Hematology/oncology clinics of North America 1992;6(2):359-69.
1992: Dimopoulos M A; Goldstein J; Fuller L; Delasalle K; Alexanian R
Curability of solitary bone plasmacytoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(4):587-90.
1991: Dimopoulos M A; Barlogie B; Smith T L; Alexanian R
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.
Annals of internal medicine 1991;115(12):931-5.
1991: Seider M J; Cleary K R; van Tassel P; Alexanian R; Schantz S P; Frias A; Fuller L M
Plasma cell granuloma of the nasal cavity treated by radiation therapy.
Cancer 1991;67(4):929-32.
1990: Jagannath S; Barlogie B; Dicke K; Alexanian R; Zagars G; Cheson B; Lemaistre F C; Smallwood L; Pruitt K; Dixon D O
Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors.
Blood 1990;76(9):1860-6.
1990: Alexanian R; Barlogie B
New treatment strategies for multiple myeloma.
American journal of hematology 1990;35(3):194-8.
1990: Barlogie B; Jagannath S; Dixon D O; Cheson B; Smallwood L; Hendrickson A; Purvis J D; Bonnem E; Alexanian R
High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma.
Blood 1990;76(4):677-80.
1990: Kantarjian H M; Alexanian R; Koller C A; Kurzrock R; Keating M J
Fludarabine therapy in macroglobulinemic lymphoma.
Blood 1990;75(10):1928-31.
1990: Ventura G J; Barlogie B; Hester J P; Yau J C; LeMaistre C F; Wallerstein R O; Spinolo J A; Dicke K A; Horwitz L H; Alexanian R
High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma.
Bone marrow transplantation 1990;5(4):265-8.
1990: Alexanian R; Barlogie B; Tucker S
VAD-based regimens as primary treatment for multiple myeloma.
American journal of hematology 1990;33(2):86-9.
1989: Barlogie B; Velasquez W S; Alexanian R; Cabanillas F
Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(10):1514-7.
1989: Barlogie B; Epstein J; Selvanayagam P; Alexanian R
Plasma cell myeloma--new biological insights and advances in therapy.
Blood 1989;73(4):865-79.
1988: Barlogie B; Alexanian R; Smallwood L; Cheson B; Dixon D; Dicke K; Cabanillas F
Prognostic factors with high-dose melphalan for refractory multiple myeloma.
Blood 1988;72(6):2015-9.
1988: Epstein J; Barlogie B; Katzmann J; Alexanian R
Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement.
Blood 1988;71(4):861-5.
1988: Selvanayagam P; Blick M; Narni F; van Tuinen P; Ledbetter D H; Alexanian R; Saunders G F; Barlogie B
Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma.
Blood 1988;71(1):30-5.
1985: Barlogie B; Alexanian R; Dixon D; Smith L; Smallwood L; Delasalle K
Prognostic implications of tumor cell DNA and RNA content in multiple myeloma.
Blood 1985;66(2):338-41.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Raymond Alexanian

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Raymond Alexanian (preview)

All Publications